Our findings contribute to this evolving evidence by suggesting that enhanced gastric FTO expression may coexist with elevated circulating adiponectin, consistent with the concept of the adiponectin paradox and the metabolically healthy obesity phenotype. The gene discussed is FTO; the disease is Obesity.